JP2024535855A5 - - Google Patents
Info
- Publication number
- JP2024535855A5 JP2024535855A5 JP2024516894A JP2024516894A JP2024535855A5 JP 2024535855 A5 JP2024535855 A5 JP 2024535855A5 JP 2024516894 A JP2024516894 A JP 2024516894A JP 2024516894 A JP2024516894 A JP 2024516894A JP 2024535855 A5 JP2024535855 A5 JP 2024535855A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- optionally
- kras
- expression system
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245703P | 2021-09-17 | 2021-09-17 | |
| US63/245,703 | 2021-09-17 | ||
| US202163281029P | 2021-11-18 | 2021-11-18 | |
| US63/281,029 | 2021-11-18 | ||
| US202263321587P | 2022-03-18 | 2022-03-18 | |
| US63/321,587 | 2022-03-18 | ||
| US202263374888P | 2022-09-07 | 2022-09-07 | |
| US63/374,888 | 2022-09-07 | ||
| PCT/US2022/076680 WO2023044493A2 (en) | 2021-09-17 | 2022-09-19 | Kras neoantigen therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535855A JP2024535855A (ja) | 2024-10-02 |
| JP2024535855A5 true JP2024535855A5 (https=) | 2025-09-29 |
Family
ID=85603659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516894A Pending JP2024535855A (ja) | 2021-09-17 | 2022-09-19 | Ｋｒａｓネオ抗原療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240238397A1 (https=) |
| EP (1) | EP4401766A4 (https=) |
| JP (1) | JP2024535855A (https=) |
| KR (1) | KR20240070547A (https=) |
| AU (1) | AU2022346048A1 (https=) |
| CA (1) | CA3231297A1 (https=) |
| IL (1) | IL311258A (https=) |
| WO (1) | WO2023044493A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024102332A1 (en) * | 2022-11-07 | 2024-05-16 | Himv Llc | Vaccine compositions comprising a neoantigen of kras |
| EP4622664A1 (en) * | 2022-11-22 | 2025-10-01 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
| WO2025213185A1 (en) * | 2024-04-05 | 2025-10-09 | Revolution Medicines, Inc. | Peptide conjugates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021092094A1 (en) * | 2019-11-04 | 2021-05-14 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared neoantigens |
| WO2021092095A1 (en) * | 2019-11-04 | 2021-05-14 | Gritstone Oncology, Inc. | Neoantigen vaccine therapy |
| KR20220098379A (ko) * | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
| CN116438308A (zh) * | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
-
2022
- 2022-09-19 IL IL311258A patent/IL311258A/en unknown
- 2022-09-19 CA CA3231297A patent/CA3231297A1/en active Pending
- 2022-09-19 WO PCT/US2022/076680 patent/WO2023044493A2/en not_active Ceased
- 2022-09-19 KR KR1020247010184A patent/KR20240070547A/ko active Pending
- 2022-09-19 AU AU2022346048A patent/AU2022346048A1/en active Pending
- 2022-09-19 JP JP2024516894A patent/JP2024535855A/ja active Pending
- 2022-09-19 EP EP22871019.0A patent/EP4401766A4/en active Pending
-
2024
- 2024-03-15 US US18/607,061 patent/US20240238397A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024535855A5 (https=) | ||
| Fu et al. | Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects | |
| Das et al. | A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity | |
| ES2741147T3 (es) | Composición de vacuna | |
| CN112912507A (zh) | 甲病毒新抗原载体和干扰素抑制剂 | |
| CA3099642A1 (en) | Immune checkpoint inhibitor co-expression vectors | |
| EP4125973A1 (en) | Neoantigen vaccine therapy | |
| JP2021532122A (ja) | 癌のための個別化ワクチン | |
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| Gabitzsch et al. | Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA | |
| KR20240070547A (ko) | Kras 신생항원 요법 | |
| JP2022512384A5 (https=) | ||
| JP2021528367A (ja) | 免疫応答を誘導するための組成物 | |
| Zhang et al. | Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy | |
| JP2023512654A5 (https=) | ||
| US20220160800A1 (en) | Methods for inducing an immune response against neoantigens | |
| JP2024534442A5 (https=) | ||
| US20220152168A1 (en) | Sequential heterologous boost oncolytic viral immunotherapy | |
| JP2023539436A (ja) | 膵臓癌の評価および処置のための方法および組成物 | |
| JP7062754B2 (ja) | ｈａＮＫセツキシマブ併用及び方法 | |
| Ren et al. | Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination | |
| WO2024240179A1 (zh) | 一种用于激活嵌合抗原受体效应细胞的中间模块分子及其应用 | |
| Ibragimova et al. | mRNA-based personalized cancer vaccines: opportunities, challenges and outcomes | |
| JP2024534442A (ja) | ネオ抗原アジュバント及び維持療法 | |
| WO2019241742A1 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |